Trial reportArchives of dermatological research2025
Comparative study between intralesional acyclovir versus intralesional 5-flurouracil in treatment of recalcitrant warts.
Trial report in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough different treatment modalities are available, the treatment of warts is still challenging with recalcitrant and recurrent lesions. Given that warts are viral in nature, acyclovir might be a viable treatment option. Intralesional acyclovir and 5-fluorouracil (5-FU) injections have been described for treating common warts and achieved a complete response in most of the patients.
aimThe aim of this work was to assess the efficacy and safety of intralesional acyclovir versus intralesional 5-flurouracil in treatment of recalcitrant cutaneous warts. PATIENTS AND
methodsThis comparative study was carried out on 60 patients diagnosed with recalcitrant cutaneous warts. The patients were categorized randomly into group I (30 patients treated with intralesional acyclovir) and group II (30 patients treated with intralesional 5-FU). Treatment was repeated every two weeks to a maximum of six sessions or until complete clearance occurred. Treatment response was assessed clinically and dermoscopically. This is the first randomized clinical trial comparing intralesional acyclovir with 5-FU for recalcitrant warts.
resultsAfter the end of 6 months of follow-up, complete clearance was achieved in 20 patients (66.7%) and 19 patients (63.3%) in the acyclovir and 5-FU groups, respectively. Also, complete clearance of all dermoscopic findings was observed in 66.7% of patients in the acyclovir group compared to 63.3% of patients in the 5-FU group, with no statistically significant difference between both groups (p > 0.001). Both modalities were safe and well tolerated.
conclusionIntralesional acyclovir and 5-FU are safe and effective methods in treatment of recalcitrant cutaneous warts.
Indexed as
Identifiers
40488756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.